Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 7 | Orphanet Journal of Rare Diseases

Figure 7

From: Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis

Figure 7

Post-Antimicrobial effect (PAE) of cysteamine, tobramycin and combinations thereof. The impact of cysteamine or tobramycin (A) and combinations thereof (B) on the recovery of growth of P. aeruginosa PAO1 cells that had been exposed to either/both of these antimicrobial agents for 16 h was monitored for 24 h post termination of cysteamine or/and tobramycin treatment at 37°C in a BioTek Synergy HT microplate reader.

Back to article page